RAPT: Rapt Therapeutics, Inc.
About
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Current Value
$1.061 Year Return
Current Value
$1.061 Year Return
Key Details
Market Cap
$37.41M
P/E Ratio
-0.38
1Y Stock Return
-92.14%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
0.4
Strategies that include RAPT
Stock's related to RAPT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EPAM | 35.78% | $12.91B | -11.78% | 0.00% |
| TRTX | 35.03% | $716.21M | +56.64% | 10.91% |
| GCMG | 35.02% | $541.48M | +44.26% | 3.64% |
| AXSM | 34.52% | $4.63B | +61.30% | 0.00% |
| MRSN | 31.12% | $274.24M | +40.51% | 0.00% |
| EXPD | 31.06% | $16.52B | +0.14% | 1.20% |
| EBS | 30.76% | $448.10M | +295.69% | 0.00% |
| EHAB | 28.27% | $365.57M | -26.27% | 0.00% |
| ABBV | 28.15% | $294.35B | +20.07% | 3.72% |
| SEER | 27.64% | $134.44M | +40.74% | 0.00% |
| STVN | 26.81% | $4.95B | -32.48% | 0.32% |
| SWTX | 26.57% | $2.82B | +79.34% | 0.00% |
| MX | 26.56% | $3.00B | +1.37% | 1.66% |
| KYMR | 26.52% | $2.77B | +125.95% | 0.00% |
| SANA | 26.22% | $526.91M | -41.15% | 0.00% |
| CHRS | 26.15% | $94.65M | -58.72% | 0.00% |
| RBLX | 26.13% | $34.28B | +42.27% | 0.00% |
| TMHC | 26.07% | $7.19B | +55.90% | 0.00% |
| SAGE | 26.05% | $300.36M | -74.61% | 0.00% |
| GCT | 26.04% | $983.16M | +147.95% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RAMP | -<0.01% | $1.86B | -16.17% | 0.00% |
| HMST | 0.01% | $215.54M | +82.88% | 0.00% |
| UFI | -0.01% | $102.66M | -11.22% | 0.00% |
| PFGC | 0.04% | $12.91B | +33.83% | 0.00% |
| YETI | -0.04% | $3.22B | -10.71% | 0.00% |
| MFC | -0.04% | $57.06B | +70.70% | 3.59% |
| SBUX | -0.05% | $111.45B | -5.15% | 2.37% |
| SHEL | 0.05% | $205.19B | -1.07% | 4.20% |
| KRRO | -0.05% | $436.84M | +20.68% | 0.00% |
| VIST | -0.07% | $4.75B | +67.10% | 0.00% |
| SFM | -0.08% | $14.34B | +254.87% | 0.00% |
| SJM | 0.09% | $11.91B | -0.25% | 3.82% |
| EDU | 0.09% | $9.06B | -22.20% | 0.00% |
| DLTH | 0.10% | $124.02M | -31.26% | 0.00% |
| CL | 0.11% | $76.48B | +22.25% | 2.12% |
| ZCMD | -0.12% | $2.80M | -88.67% | 0.00% |
| CYCN | 0.13% | $4.77M | -16.19% | 0.00% |
| UIS | 0.14% | $511.20M | +51.33% | 0.00% |
| CRWD | 0.14% | $86.61B | +69.05% | 0.00% |
| CME | 0.16% | $82.76B | +9.21% | 1.98% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LUNR | -23.87% | $790.33M | +333.10% | 0.00% |
| WES | -23.28% | $14.38B | +32.63% | 8.48% |
| MFIN | -22.84% | - | - | 4.31% |
| VZIO | -19.59% | $2.29B | +67.76% | 0.00% |
| PANW | -19.02% | $126.99B | +46.98% | 0.00% |
| KEP | -15.34% | $11.16B | +25.58% | 0.00% |
| BCS | -14.34% | $47.29B | +83.45% | 3.18% |
| AGS | -13.70% | $479.25M | +57.18% | 0.00% |
| AWI | -13.69% | $6.69B | +84.16% | 0.75% |
| VRSK | -13.67% | $39.77B | +17.45% | 0.53% |
| EMBC | -13.34% | $777.82M | -20.98% | 4.49% |
| SPTN | -13.17% | $615.01M | -17.44% | 4.80% |
| GIS | -13.15% | $34.85B | -2.91% | 3.78% |
| CAG | -13.10% | $12.64B | -6.10% | 5.26% |
| CBOE | -12.84% | $21.46B | +15.84% | 1.11% |
| WOW | -11.22% | $434.90M | +18.48% | 0.00% |
| TXO | -11.15% | $737.26M | -1.80% | 13.22% |
| ASPS | -10.90% | $22.36M | -80.26% | 0.00% |
| HSBC | -10.85% | $167.25B | +22.83% | 6.59% |
| PULM | -10.51% | $19.83M | +202.98% | 0.00% |
ETF's related to RAPT
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 32.26% | $6.58B | 0.35% |
| RSPA | 32.10% | $273.87M | 0% |
| IBB | 31.89% | $6.66B | 0.45% |
| XPH | 31.76% | $157.87M | 0.35% |
| QQA | 31.21% | $135.01M | 0% |
| PBE | 30.80% | $258.53M | 0.58% |
| FBT | 29.80% | $1.11B | 0.56% |
| GNOM | 28.23% | $70.59M | 0.5% |
| PTH | 27.46% | $143.31M | 0.6% |
| BBH | 27.22% | $397.87M | 0.35% |
| IWC | 27.17% | $933.99M | 0.6% |
| PBW | 25.87% | $301.18M | 0.65% |
| VHT | 25.64% | $17.06B | 0.1% |
| ARKK | 25.49% | $6.28B | 0.75% |
| FHLC | 25.49% | $2.73B | 0.084% |
| SLYG | 25.24% | $3.69B | 0.15% |
| PINK | 25.14% | $161.15M | 0.5% |
| IHE | 25.05% | $596.23M | 0.39% |
| VBK | 25.04% | $19.31B | 0.07% |
| EDOC | 24.94% | $40.86M | 0.68% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CTA | -0.09% | $350.27M | 0.78% |
| XHLF | -0.34% | $874.27M | 0.03% |
| ICSH | 0.36% | $5.57B | 0.08% |
| VNLA | 0.36% | $2.27B | 0.23% |
| AGZD | 0.50% | $142.76M | 0.23% |
| DBO | -0.72% | $217.57M | 0.77% |
| COMT | 0.90% | $829.06M | 0.48% |
| FLOT | 1.26% | $7.31B | 0.15% |
| SHV | -1.47% | $18.13B | 0.15% |
| TBIL | -1.61% | $4.38B | 0.15% |
| MLPA | 1.83% | $1.64B | 0.45% |
| GBIL | 1.83% | $5.60B | 0.12% |
| IBMM | -1.86% | $391.28M | 0.18% |
| FLTR | 1.88% | $1.79B | 0.14% |
| FTSM | 2.03% | $6.08B | 0.45% |
| USCI | 2.05% | $185.47M | 1.07% |
| BCI | 2.11% | $1.20B | 0.26% |
| SEIX | 2.20% | $268.81M | 0.62% |
| KCCA | -2.40% | $220.51M | 0.87% |
| AMLP | 2.45% | $9.45B | 0.85% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -17.63% | $388.04M | 1.43% |
| VIXY | -13.96% | $195.31M | 0.85% |
| IBTE | -12.29% | $1.70B | 0.07% |
| UUP | -9.81% | $309.25M | 0.77% |
| JUCY | -9.28% | $324.29M | 0.6% |
| TPMN | -8.92% | $40.60M | 0.65% |
| USDU | -8.51% | $201.97M | 0.5% |
| WEAT | -8.41% | $120.27M | 0.28% |
| TAIL | -8.04% | $67.98M | 0.59% |
| SOYB | -7.49% | $27.32M | 0.22% |
| EQLS | -7.21% | $76.08M | 1% |
| CORN | -6.57% | $61.12M | 0.2% |
| BOXX | -6.56% | $4.43B | 0.1949% |
| DBA | -6.15% | $755.88M | 0.93% |
| BILZ | -5.84% | $563.02M | 0.14% |
| XBIL | -4.67% | $637.70M | 0.15% |
| MINT | -3.85% | $11.62B | 0.35% |
| HDRO | -3.68% | $164.26M | 0.3% |
| SGOV | -3.62% | $27.53B | 0.09% |
| TBLL | -3.21% | $1.92B | 0.08% |
News
Yahoo
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2024. Financial Results for the Third Quarter and Nine Months Ended September 30, 20
Yahoo
The trials were placed on hold earlier this year due to a serious adverse event in a patient.
Yahoo
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunitiesSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it is terminating its zelnecirnon (
Finnhub
By Ben Glickman Rapt Therapeutics said Monday it would stop developing its one of its lead drug candidates after a patient had a reaction that required a liver transplant. The South San...
Yahoo
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.